A Director at Bio-Techne is Exercising Options

Yesterday it was reported that a Director at Bio-Techne (TECHResearch Report), Robert Baumgartner, exercised options to sell 5,000 TECH shares at $66.90 a share, for a total transaction value of $1.52M.

Following Robert Baumgartner’s last TECH Sell transaction on May 26, 2020, the stock climbed by 44.8%. In addition to Robert Baumgartner, 3 other TECH executives reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Bio-Techne’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $204 million and quarterly net profit of $33.4 million. In comparison, last year the company earned revenue of $183 million and had a net profit of $14.4 million. The company has a one-year high of $316.87 and a one-year low of $155.17. TECH’s market cap is $11.77 billion and the company has a P/E ratio of 48.30.

Based on 8 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $331.71, reflecting a -9.1% downside.

The insider sentiment on Bio-Techne has been negative according to 46 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.